The mRNA vaccines were developed using novel technology that was approved for the first time for public use during the COVID-19 pandemic.

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

The FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under ...

A group of experts who advise the US Food and Drug Administration on its vaccine decisions voted unanimously Thursday to make ...

Moderna had designs on releasing a combined influenza and covid-19 vaccine after some promising trials, but this week the ...

Analysts have set 12-month price targets for Moderna, revealing an average target of $37.62, a high estimate of $70.00, and a ...

An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 ...

FDA now requires Pfizer and Moderna COVID-19 vaccines to carry expanded warning labels about risks of myocarditis and pericarditis ...

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter ...

Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...